How are energy investors positioned?
INNSBRUCK, Austria - Bruker Corporation (NASDAQ:BRKR), a global provider of scientific instruments with a market capitalization of $5.57 billion, announced the acquisition of biocrates life sciences ag, an Austrian firm specializing in mass spectrometry-based metabolomics kits and services. The financial details of the transaction, which aims to enhance Bruker’s multiomics strategy, were not disclosed. According to InvestingPro analysis, Bruker currently appears undervalued based on its Fair Value assessment, with the stock trading near its 52-week low of $34.10.
Biocrates is recognized for its quantitative metabolite and lipid analysis kits, which facilitate standardized metabolomics for laboratories around the world. The company’s kits can quantify over 1,000 metabolites from more than 40 classes, integrating sample preparation, identification, and data analysis. This acquisition is expected to bolster Bruker’s metabolomics solutions and support its expansion into multiomics, which includes instruments, reagents, software, and research services. The move comes as Bruker demonstrates strong financial performance, with revenue growth of 14.84% in the last twelve months and maintaining a GOOD overall financial health score according to InvestingPro metrics.
The acquisition builds on Bruker’s previous purchases in the multiomics field, including proteomics companies PreOmics and Biognosys. Dr. Oliver Rinner, Bruker’s Vice President for Enabling Multiomics Solutions and Biognosys founder, emphasized the significance of multiomics in the future of life sciences and biopharma R&D, highlighting biocrates’ role in completing Bruker’s portfolio with essential metabolomics solutions.
Matt Lewis, Ph.D., Bruker Vice President of Metabolomics & Lipidomics, mentioned that incorporating biocrates’ expertise in quantitation and workflow automation will accelerate the application of MS-based omics technologies and advance their shared multiomics vision.
Moritz Seuster, CEO of biocrates, expressed enthusiasm for the partnership with Bruker, emphasizing a shared commitment to multiomics technologies and the goal of making omics quantitative, reproducible, and accessible.
Bruker is known for its contributions to post-genomic discoveries and applications that improve human life quality. The company provides a range of scientific instruments and analytical solutions for molecular, cellular, and microscopic exploration in various research and industrial fields. With a gross profit margin of 49.9% and positive earnings expectations for the year, Bruker demonstrates solid operational efficiency. For deeper insights into Bruker’s financial health and growth prospects, investors can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports, available for over 1,400 US stocks.
Biocrates, established in 2002, is a leader in mass-spectrometry-based metabolomics, offering standardized kits, software, and services for biomarker quantification. Researchers use its products, such as the MxP® Quant 1000 kit, to convert metabolic data into actionable biomarkers and to advance drug development and healthcare precision.
The information in this article is based on a press release statement.
In other recent news, Bruker Corporation has made several notable announcements at the 73rd Conference on Mass Spectrometry and Allied Topics. The company introduced the timsUltra AIP mass spectrometer, which enhances sensitivity for proteomics research, promising up to 35% more peptide and 20% more protein identifications. Additionally, Bruker launched the timsOmni system, integrating advanced capabilities for analyzing proteoforms, which are crucial in understanding diseases like cancer and neurodegeneration. The timsMetabo system was also unveiled, offering improved analysis of small molecules in metabolomics and lipidomics research. Furthermore, Bruker introduced the MOVE-T, a liquid dairy analyzer using FT-NIR technology for enhanced quality control in the dairy industry. Meanwhile, Citi analysts downgraded Bruker’s stock from Buy to Neutral, reducing the price target to $40 due to concerns about order volatility in the U.S. Academic and Government market and potential European Union tariffs. These developments reflect Bruker’s ongoing commitment to innovation in scientific instrumentation while facing market challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.